rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Sabra Health Care REIT, Inc.

SBRA · Nasdaq

Real EstateREITsNot moving yet

SBRA stood above a rising 150-day average in 40 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 3.7% below that average now. REITs: 11% of its 170 stocks in an uptrend (−10 points in four weeks); Real Estate: 11% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 5
Industry in uptrend
11% -10 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$8.9M
Officials’ trades on record
15

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 40 of 52 weeks.

17 Apr – 16 Oct
12%33%54%Apr 26Jun 26Jul 26Sep 26Oct 26

REITs: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Real Estate: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$8.0M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

15 disclosed lines: House 15, Senate 0, executive 0; 6 people.

WhoDidAmountTraded
Daniel S. Goldman House: U.S. House ClerkNY10sold$1k–$15k10 Apr 2023filed 19 May 2023
Daniel S. Goldman House: U.S. House ClerkNY10bought$1k–$15k1 Mar 2023filed 17 Apr 2023
Chris Jacobs House: U.S. House ClerkNY27sold$1k–$15k8 Nov 2022filed 12 Dec 2022
Chris Jacobs House: U.S. House ClerkNY27bought$15k–$50k21 Jun 2022filed 28 Jul 2022
Lois Frankel House: U.S. House ClerkFL21sold$1k–$15k11 Mar 2019filed 27 Mar 2019
Lois Frankel House: U.S. House ClerkFL21sold$1k–$15k8 Mar 2019filed 27 Mar 2019
Greg Gianforte House: U.S. House ClerkMT00bought$50k–$100k21 Dec 2018filed 23 Jan 2019
Gary J. Palmer House: U.S. House ClerkAL06bought$1k–$15k6 Aug 2018filed 29 Sep 2018
Gary J. Palmer House: U.S. House ClerkAL06boughtjoint$1k–$15k12 Jul 2018filed 29 Sep 2018
Lois Frankel House: U.S. House ClerkFL21bought$1k–$15k2 Oct 2017filed 3 Nov 2017
Lois Frankel House: U.S. House ClerkFL21bought$1k–$15k29 Sep 2017filed 3 Nov 2017
Thomas MacArthur House: U.S. House ClerkNJ03sold$15k–$50k1 Feb 2016filed 3 Mar 2016

Insiders

Buy orders, 12 months0
Sale orders, 12 months2
Buyers · sellers0 · 2
WhoDidSharesTraded
Richard K. MatrosChair, CEO and Presidentsold200,000at $20.838 Sep 2026filed 9 Sep 2026
Jessica FloresExecutive VP & CAOsold15,231at $19.8625 Mar 2026filed 26 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

News

No headline names it lately.

Everyone who traded it

Richard K. Matros Company insiderChair, CEO and President · last 8 Sep 20262 · 2
Ann Kono Company insiderDirector · last 31 Aug 20260 · 0
Catherine Cusack Company insiderDirector · last 31 Aug 20266 · 0
Craig A. Barbarosh Company insiderDirector · last 31 Aug 20264 · 0
Darrin Smith Company insiderExecutive VP, CIO & Secretary · last 31 Aug 20260 · 0
Jeffrey A. Malehorn Company insiderDirector · last 31 Aug 20260 · 0
Jessica Flores Company insiderExecutive VP & CAO · last 31 Aug 20260 · 1
Lynne S. Katzmann Company insiderDirector · last 31 Aug 20260 · 0
Michael J. Foster Company insiderDirector · last 31 Aug 20266 · 4
Michael Lourenco Costa Company insiderExecutive VP, CFO & Treasurer · last 31 Aug 20261 · 0
Talya Nevo-Hacohen Company insiderExecutive VP, CIO & Treasurer · last 28 Nov 20252 · 0
Clifton J. Porter II Company insiderDirector · last 30 May 20250 · 0

Same industry

CXW CoreCivicLeading+12%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Cash conversionFY 2025 · to 31 Dec 2025224%
Debt to equityFY 2025 · to 31 Dec 20250.90×
Share count trendFY 2025 · to 4 Feb 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$71.5M

Analyst forecasts

No analyst forecasts yet.